Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma | Zendy

Daniel Stellato | Zendy; Marroon Thabane | Zendy; Carly Eichten | Zendy; Thomas E. Delea | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma

Author(s) -

Daniel Stellato,

Marroon Thabane,

Carly Eichten,

Thomas E. Delea

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.5085

Subject(s) - medicine , trametinib , dabrafenib , pembrolizumab , melanoma , adverse effect , family medicine , regimen , adjuvant , quality of life (healthcare) , cancer , oncology , vemurafenib , metastatic melanoma , immunotherapy , nursing , mapk/erk pathway , kinase , cancer research , biology , microbiology and biotechnology

Past research suggests that patients with early- and late-stage melanoma will endure adverse events and inconvenient treatment regimens for improved survival. Evidence about the preferences of Canadian patients and physicians for novel adjuvant treatments for melanoma is unavailable.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research